Tags

Type your tag names separated by a space and hit enter

Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
Neurology. 2010 Jul 13; 75(2):143-51.Neur

Abstract

OBJECTIVE

To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials.

METHODS

We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Abeta(1-42)) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD).

RESULTS

There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE epsilon4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures.

CONCLUSIONS

Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.

Authors+Show Affiliations

Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

20625167

Citation

Vemuri, P, et al. "Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD." Neurology, vol. 75, no. 2, 2010, pp. 143-51.
Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75(2):143-51.
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., & Jack, C. R. (2010). Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology, 75(2), 143-51. https://doi.org/10.1212/WNL.0b013e3181e7ca82
Vemuri P, et al. Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD. Neurology. 2010 Jul 13;75(2):143-51. PubMed PMID: 20625167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serial MRI and CSF biomarkers in normal aging, MCI, and AD. AU - Vemuri,P, AU - Wiste,H J, AU - Weigand,S D, AU - Knopman,D S, AU - Trojanowski,J Q, AU - Shaw,L M, AU - Bernstein,M A, AU - Aisen,P S, AU - Weiner,M, AU - Petersen,R C, AU - Jack,C R,Jr AU - ,, PY - 2010/7/14/entrez PY - 2010/7/14/pubmed PY - 2010/7/31/medline SP - 143 EP - 51 JF - Neurology JO - Neurology VL - 75 IS - 2 N2 - OBJECTIVE: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. METHODS: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Abeta(1-42)) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). RESULTS: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE epsilon4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. CONCLUSIONS: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/20625167/Serial_MRI_and_CSF_biomarkers_in_normal_aging_MCI_and_AD_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=20625167 DB - PRIME DP - Unbound Medicine ER -